EntrepreneurshipThe Strüngmann legacy, passed onThomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family … more ➔
heart attackResoTher heart data clear acquisition hurdle, set up 200-patient trialDanish biotech ResoTher Pharma’s heart attack drug RTP-026 was well tolerated and showed early efficacy signals in a 66-patient Phase 2a trial, according to results announced Sept. 14 that clear a key … more ➔
myelomaGSK returns to Chimagen for up to $750M myeloma trispecificGSK has agreed to acquire full global rights to a preclinical trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences in a deal worth up to $750 million (€650 million), … more ➔
clinical dataAgomab’s IPF drug clears first patient testAgomab Therapeutics’ inhaled idiopathic pulmonary fibrosis (IPF) drug AGMB-447 showed lung-restricted exposure and inhibited its intended target in its first patient trial. The company plans to move … more ➔
MaaT PharmaMaaT’s bid to overturn microbiome approval refusal suffers setbackMaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy. more ➔
clinical dataAxoltis ALS drug misses Phase 2 endpointFrench biotech Axoltis Pharma’s NX210c missed the primary endpoint of a Phase 2 trial in amyotrophic lateral sclerosis (ALS), but post-hoc analyses showing slower functional decline are giving the … more ➔
StrategyCellectis scraps CAR-T pipeline in gene editing pivotFrench biotech Cellectis is abandoning development of its two internal allogeneic CAR-T programs and repositioning itself as an in vivo gene editing company focused initially on cardiovascular disea … more ➔
MAES-AREA-Englosclinical trialGenfit plans Phase 2 liver failure trial after acquiring immunomodulator from InotremFrench biotech Genfit acquired nangibotide from Inotrem in the summer and plans to start a Phase 2a trial in acute-on-chronic liver failure (ACLF) in the fourth quarter. more ➔
clinical dataGSK and Roche Chinese ADC bets deliver positive phase 3 data in SCLCTwo B7-H3-targeted antibody-drug conjugates licensed from Chinese biotechs have now delivered positive phase 3 survival data in relapsed small-cell lung cancer, strengthening the oncology bets GSK and … more ➔
BioNTech SEOncologyBioNTech adds clinical weight to its oncology pivot at WCLC 2026New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its mRNA platform. Gotistobart has shown a marked survival benefit in previously … more ➔
MAES-AREA-Englos
BioNTech SE